Edition:
United States

Danaher Corp (DHR.N)

DHR.N on New York Stock Exchange

77.22USD
3:20pm EST
Change (% chg)

$-0.10 (-0.13%)
Prev Close
$77.32
Open
$77.71
Day's High
$77.80
Day's Low
$77.02
Volume
337,720
Avg. Vol
913,166
52-wk High
$82.14
52-wk Low
$61.58

Select another date:

Tue, Oct 25 2016

BRIEF-Danaher enters new $3 bln 364-day revolving credit facility

* Danaher Corp says on Oct. 24 entered into a new $3.0 billion 364-day revolving credit facility with Morgan Stanley Senior Funding, Inc

BRIEF-Cepheid receives required regulatory clearances in proposed acquisition by Danaher

* Cepheid announces receipt of required regulatory clearances in proposed acquisition by Danaher Corporation Source text for Eikon: Further company coverage:

BRIEF-Danaher reports Q3 earnings per share $0.57

* Q3 earnings per share view $0.82 -- Thomson Reuters I/B/E/S

BRIEF-S&P places Danaher Corp. 'A' ratings on watch negative on planned acqusition of Cepheid

* S&P - Danaher Corp. 'A' ratings placed on watch negative on planned acqusition of Cepheid

Danaher to buy Cepheid in $4 billion deal to expand in diagnostics

Danaher Corp said on Tuesday it would buy medical diagnostics company Cepheid in a deal valued at $4 billion, including debt, that will strengthen its presence in molecular diagnostics.

UPDATE 3-Danaher to buy Cepheid in $4 bln deal to expand in diagnostics

Sept 6 Danaher Corp said on Tuesday it would buy medical diagnostics company Cepheid in a deal valued at $4 billion, including debt, that will strengthen its presence in molecular diagnostics.

BRIEF-Moody's says Danaher's A2 rating unaffected by planned acquisition of Cepheid

* Moody's: Danaher's A2 rating unaffected by planned acquisition of Cepheid for $4 billion Source text for Eikon: Further company coverage:,

BRIEF-Danaher to acquire Cepheid for $53.00 per share, or about $4 billion

* Danaher to acquire Cepheid for $53.00 per share, or approximately $4 billion

Danaher to buy Cepheid for about $4 bln, including debt

Sept 6 Danaher Corp said it would buy molecular diagnostics company Cepheid in a deal valued at $4 billion, including debt.

BRIEF-Danaher Corporation to redeem senior notes

* Danaher corp says it will also redeem all of its $600 million aggregate principal amount of 3.900% senior notes due 2021

Select another date: